Country: Norway
Language: Norwegian
Source: Statens legemiddelverk
Mertiatid
ROTOP Pharmaka GmbH
V09CA03
Mertiatid
0.2 mg/2.5 ml
Preparasjonssett til radioaktive legemidler
5 sett
C
Markedsført
2006-09-29
1 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT NephroMAG, 0.2 mg, Kit for radiopharmaceutical preparation 2. QUALITATIVE AND QUANTITATIVE COMPOSITION The kit contains two different vials: (1) and (2). Vial (1) contains 0.2 mg of the mercaptoacetyltriglycine (mertiatide). Vial (2) contains 2.5 mL phosphate buffer solution. For a full list of excipients, see section 6.1. The radioisotope is not part of the kit. The kit contains all non radioactive components required for the reconsitution of technetium-(99mTc) mertiatide solution for injection. 3. PHARMACEUTICAL FORM Kit for radiopharmaceutical preparation. Properties of the product after labelling: Clear to slightly opalescent, colourless, aqueous solution. pH: 7.1-7.5 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS This medicinal product is for diagnostic use only. After reconstitution and labelling with sodium pertechnetate(99mTc) solution, the radiopharmaceutical product obtained, technetium-(99mTc) mertiatide, is used for the evaluation of nephrological and urological disorders in particular for the study of function, morphology and perfusion of the kidneys and characterisation of urinary outflow. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION ADULTS AND ELDERLY Adults and elderly: 40 - 200 MBq,_ _depending on the pathology to be studied and the method to be used. POPULATION AGED LESS THAN 18 YEARS Although NephroMAG may be used in paediatric patients, formal studies have not been performed. Clinical experience indicates that, for paediatric use, the activity should be reduced. Because of the variable relationship between the size and body weight of patients, it is sometimes more satisfactory to adjust activities to body surface area. A practical approach is to adopt the recommendations of the Paediatric Task Group of the European Association of Nuclear Medicine (EANM). See table below. Reduction of the radioactivity to less than 10 % of the adult activity would generally result in technically unsatisfactory procedures. 2 Fraction of adul Read the complete document